Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary) ; Metformin; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms HARMONY 1; HARMONY-1
- Sponsors GlaxoSmithKline; GSK
- 10 Jun 2021 According to a Harmony Biopharm media release, data from this trial was presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS).
- 10 Jun 2021 Results published in Harmony Biosciences Media Release
- 14 Oct 2020 According to a Harmony Biosciences media release, U.S. Food and Drug Administration (FDA) has approved WAKIX(pitolisant) for the treatment of cataplexy in adult patients with narcolepsy.FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from HARMONY CTP and HARMONY 1 from the clinical development program for WAKIX.